-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Coherus Biosciences (CHRS): "buying opportunity ahead of key catalysts"
-
-
-
-
-
-
-
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Misses Q2 EPS by 8c
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Announces Repurchase of Approximately $170M of Convertible Notes
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Misses Q1 EPS by 7c, provides R&D and SG&A expense guidance
-
-
-
-
-
-
-
Surface Oncology (SURF) Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences (CHRS)
-
-
-
-
-
-
-
Coherus BioSciences (CHRS) Misses Q3 EPS by 22c, Misses on Revenue
-
1,217,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

